Bolt Biotherapeutics Revenue and Competitors

Location

$198.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Bolt Biotherapeutics's estimated annual revenue is currently $15.7M per year.(i)
  • Bolt Biotherapeutics's estimated revenue per employee is $155,000
  • Bolt Biotherapeutics's total funding is $198.5M.
  • Bolt Biotherapeutics's current valuation is $144.7M. (January 2022)

Employee Data

  • Bolt Biotherapeutics has 101 Employees.(i)
  • Bolt Biotherapeutics grew their employee count by 1% last year.

Bolt Biotherapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Chief Medical OfficerReveal Email/Phone
3
VP BiometricsReveal Email/Phone
4
VP Clinical DevelopmentReveal Email/Phone
5
VP CMC and QualityReveal Email/Phone
6
VP, Head Regulatory AffairsReveal Email/Phone
7
VP, Head BiometricsReveal Email/Phone
8
VP Clinical OperationsReveal Email/Phone
9
VP FinanceReveal Email/Phone
10
VP Program ManagementReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Bolt Biotherapeutics?

Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman?s Lab at Stanford University, which demonstrated complete cures in numerous cancer models. The company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company?s future leaders to help it further develop and bring to patients novel and curative biotherapies.

keywords:N/A

$198.5M

Total Funding

101

Number of Employees

$15.7M

Revenue (est)

1%

Employee Growth %

$144.7M

Valuation

N/A

Accelerator

Bolt Biotherapeutics News

2022-04-06 - Bolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conference - Benzinga

In addition, Bolt Bio is developing new immuno-oncology Boltbody ISACs through strategic collaborations with leading biopharmaceutical companies...

2022-03-30 - Bolt Biotherapeutics Reports Four Quarter and Full Year 2021 ...

About Bolt Biotherapeutics, Inc. Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology...

2022-03-30 - Bolt Therapeutics files for $250M mixed shelf offering

Bolt Therapeutics files for $250M mixed shelf offering. Mar. 30, 2022 6:07 PM ETBolt Biotherapeutics, Inc. (BOLT)By: Jonathan Block, SA News Editor1 Comment.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21M104-4%N/A
#2
$21.4M10514%$51M
#3
$15.2M1052%$24.2M
#4
$18.7M10710%N/A
#5
$17.1M110-29%$319M